NEW YORK (GenomeWeb News) – Oxford Immunotec and Lophius Biosciences said today that they have signed agreements providing each other access to certain intellectual property.
As a result, Oxford Immunotec will be able to develop novel T-cell-based assays using Lophius' Urea technology and commercialize them in certain geographies. Lophius, which announced last week that it raised $5.3 million, can develop and commercialize novel T-cell-based assays under a license from Oxford Immunotec for its T-Spot technology.
Financial and other terms of the deals were not disclosed.
"We believe that Lophius' Urea technology has distinct advantages over conventional methods of designing and producing antigens for T-cell-based diagnostic systems," Peter Wrighton-Smith, CEO of Oxford Immunotec, said in a statement. "We are looking forward to combining Lophius' technology with our own, to develop and launch innovative new assays for infectious and immunological disease."
Based in Oxford, UK, Oxford Immunotec develops immunology-focused diagnostics. Lophius, headquartered in Regensburg, Germany, develops T-cell-based tests for diagnostic purposes and as possible therapy controls in transplantation, infection, and autoimmune diseases.